- •SARS-CoV-2 infection after the first BNT162b2 dose does not boost antibody response.
- •A postponed second dose induced antibody titres similar to those in naïve vaccinees.
- •We advise a second vaccine dose for individuals infected early after the first dose.
- Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.J Infect. 2021; (Jun 20S0163-4453(21)00314-5)https://doi.org/10.1016/j.jinf.2021.06.017
- Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine.N Engl J Med. 2021; https://doi.org/10.1056/NEJMc2101667
- Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection.Viruses. 2021; 13: 422https://doi.org/10.3390/v13030422
- Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.Clin Microbiol Infect. 2021; https://doi.org/10.1016/j.cmi.2021.07.024
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.Nat Med. 2021; 27: 1205-1211https://doi.org/10.1038/s41591-021-01377-8
- A correlate of protection for SARS-CoV-2 vaccines is urgently needed.Nat Med. 2021; 27: 1147-1148https://doi.org/10.1038/s41591-021-01432-4
- Neutralising capacity against delta (B.1.617.2) and other variants of concern following comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.Euro Surveill. 2021; 26https://doi.org/10.2807/1560-7917.ES.2021.26.26.2100557
- BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.Lancet Respir Med. 2021; (S2213-2600(21)00220-4)https://doi.org/10.1016/S2213-2600(21)00220-4